DNLI - Biogen Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

• Biogen ( NASDAQ: BIIB ) and Denali Therapeutics ( NASDAQ: DNLI ) have commenced dosing in the phase 3 LIGHTHOUSE study examining BIIB122 for Parkinson’s disease in those with a certain genetic mutation.
• The primary endpoint is time to confirmed worsening based on the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
• The study will enroll ~400 participants with Parkinson’s and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene. These mutations are the most frequent ones found in Parkinson's.
• The study will last 180 weeks. Participants will be randomized to receive either BIIB122 or placebo once a day.
• Seeking Alpha's Quant Rating views Denali Therpeutics ( DNLI ) as a buy with high marks for profitability and momentum .

For further details see: